Pharmaceutical News

RSS

FDA issues warning on blood pressure drug, olmesartan medoxomil

Food and Drug Administration (FDA) regulators have issued a warning on the blood pressure drug known generically as olmesartan medoxomil. The drug can cause intestinal problems known as spruelike enteropathy, which has side effects including severe, chronic diarrhea and substantial weight loss, sometimes requiring hospitalization.

11 Jul 2013

Research shows proton pump inhibitors may cause cardiovascular problems

Drugs that help millions of people cope with acid reflux may also cause cardiovascular disease, report scientists from Houston Methodist Hospital and two other institutions in an upcoming issue of Circulation (now online). It is the first time researchers have shown how proton pump inhibitors, or PPIs, might cause cardiovascular problems.

11 Jul 2013

MDPV stimulant effects could be more addictive than methamphetamine, say TSRI researchers

Scientists at The Scripps Research Institute have published one of the first laboratory studies of MDPV, an emerging recreational drug that has been sold as “bath salts.”

11 Jul 2013

NPS MedicineWise calls on every Australian to fight against antibiotic resistance

In light of a paper released by the Office of the Chief Scientist today, NPS MedicineWise is calling on every Australian to do their part in the fight against antibiotic resistance in our community.

11 Jul 2013

Researchers confirm that bath salts could be more addictive than methamphetamine

Scientists at The Scripps Research Institute (TSRI) have published one of the first laboratory studies of MDPV, an emerging recreational drug that has been sold as "bath salts." The TSRI researchers confirmed the drug's powerful stimulant effects in rats and found evidence that it could be more addictive than methamphetamine, one of the most addictive substances to date.

11 Jul 2013

New concept could improve cancer drug delivery

Researchers have developed a concept to potentially improve delivery of drugs for cancer treatment using nanoparticles that concentrate and expand in the presence of higher acidity found in tumor cells.

11 Jul 2013

Pharmacyclics submits ibrutinib NDA to FDA for two B-cell malignancies

Pharmacyclics, Inc. today announced that it has submitted a New Drug Application to the U.S. Food and Drug Administration for the investigational oral Bruton's tyrosine kinase inhibitor, ibrutinib, for two relapsed/refractory B-cell malignancy indications: mantle cell lymphoma and chronic lymphocytic leukemia/small lymphocytic lymphoma.

10 Jul 2013

Pfizer's Prevenar 13 receives European approval to include adults for prevention of invasive disease

Pfizer Inc. announced today the company's pneumococcal conjugate vaccine, Prevenar 13 (pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]), received European approval for an expanded indication to include adults aged 18 to 49 years for active immunization for the prevention of invasive disease caused by vaccine-type Streptococcus pneumoniae (S. pneumoniae).

10 Jul 2013

Acetaminophen overdose survivors have lower overall health following acute liver failure

Spontaneous survivors of acetaminophen overdose have significantly lower overall health compared to survivors or transplant recipients following acute liver failure caused by non-drug induced liver injury according to a new study published online in Liver Transplantation, a journal of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

10 Jul 2013

UBC researchers develop vaccine to halt spread of West Nile Virus in birds

University of British Columbia researchers have developed a vaccine that may halt the spread of West Nile Virus among common and endangered bird species.

10 Jul 2013

Dual antiplatelet therapy improves outcomes in patients undergoing coronary stenting

Emmanouil S. Brilakis, M.D., Ph.D., of the VA North Texas Health Care System and University of Texas Southwestern Medical Center at Dallas, and colleagues conducted a review of medical literature regarding optimal medical therapy after percutaneous coronary intervention (PCI; procedures such as balloon angioplasty or stent placement used to open narrowed coronary arteries).

10 Jul 2013

AOSSM presents awards and grants to encourage research in orthopaedic sports medicine

In order to recognize and encourage cutting-edge research in key areas of orthopaedic sports medicine, the American Orthopaedic Society for Sports Medicine (AOSSM) will present ten research awards and seven grants during its Annual Meeting, July 11-14 in Chicago, IL.

10 Jul 2013

Researchers discover new class of antimalarial compounds

Despite renewed global efforts for eradication, malaria continues to exert devastating effects on human health. An estimated 220 million people are infected each year by malaria-causing Plasmodium parasites, which are transmitted by the bite of an infected mosquito. This enormous infection burden leads to some 660,000 lives lost to malaria each year, the majority of these young children in sub-Saharan Africa. While a vaccine to prevent malaria remains elusive, we depend on antimalarial compounds both to treat infections and prevent disease.

10 Jul 2013

Immunocore, GSK partner for cancer targeting ImmTACs

Immunocore Limited, the Oxford-based biotechnology company developing novel biological drugs called ImmTACs to treat cancer and viral disease, today announced it has entered into a partnership with GlaxoSmithKline (GSK) for multiple novel targets not addressable using antibody-based technologies. This is Immunocore’s second major partnership this year.

10 Jul 2013

TGA of Australia approves Vertex Pharmaceuticals' KALYDECO for cystic fibrosis

Vertex Pharmaceuticals Incorporated today announced that the Therapeutic Goods Administration of Australia has approved KALYDECO (ivacaftor) for people with cystic fibrosis ages 6 and older who have at least one copy of the G551D mutation in the cystic fibrosis transmembrane conductance regulator gene.

10 Jul 2013

Diclegis delayed-release tablets for NVP treatment now eligible for Medicaid coverage

Duchesnay USA today announced that Diclegis (doxylamine succinate 10mg, pyridoxine hydrochloride 10mg) delayed-release tablets for the treatment of nausea and vomiting of pregnancy, more commonly known as morning sickness, is now available for coverage under the state and federal Medicaid program effective July 1st, 2013.

9 Jul 2013

Acorda Therapeutics acquires two neuropathic pain management assets from NeurogesX

Acorda Therapeutics, Inc. today announced that it has acquired two neuropathic pain management assets from NeurogesX, Inc. Qutenza is approved by the U.S. Food and Drug Administration for the management of neuropathic pain associated with postherpetic neuralgia.

9 Jul 2013

Omthera submits Epanova NDA to FDA for treatment of severe hypertriglyceridemia

Omthera Pharmaceuticals, Inc., an emerging specialty pharmaceutical company, today announced that it has submitted a New Drug Application to the U.S. Food and Drug Administration seeking approval for the marketing and sale of Epanova™ for the treatment for patients with severe hypertriglyceridemia (triglyceride levels greater than or equal to 500mg/dL).

9 Jul 2013

A few clinics are focused on helping pregnant women with prescription drug addictions

The Wall Street Journal examines the growing number of women addicted to pain killers and efforts to help them through pregnancies.

9 Jul 2013

ERC awards grants to boost research on vaccines

Vaccination has achieved huge success in controlling many devastating infectious diseases. However, there are still many such diseases, or 'pathogens', against which we cannot generate life-long protective immunity.

9 Jul 2013

Pharmaceutical News

FDA issues warning on blood pressure drug, olmesartan medoxomil

Research shows proton pump inhibitors may cause cardiovascular problems

MDPV stimulant effects could be more addictive than methamphetamine, say TSRI researchers

NPS MedicineWise calls on every Australian to fight against antibiotic resistance

Researchers confirm that bath salts could be more addictive than methamphetamine

New concept could improve cancer drug delivery

Pharmacyclics submits ibrutinib NDA to FDA for two B-cell malignancies

Pfizer's Prevenar 13 receives European approval to include adults for prevention of invasive disease

Acetaminophen overdose survivors have lower overall health following acute liver failure

UBC researchers develop vaccine to halt spread of West Nile Virus in birds

Dual antiplatelet therapy improves outcomes in patients undergoing coronary stenting

AOSSM presents awards and grants to encourage research in orthopaedic sports medicine

Researchers discover new class of antimalarial compounds

Immunocore, GSK partner for cancer targeting ImmTACs

TGA of Australia approves Vertex Pharmaceuticals' KALYDECO for cystic fibrosis

Diclegis delayed-release tablets for NVP treatment now eligible for Medicaid coverage

Acorda Therapeutics acquires two neuropathic pain management assets from NeurogesX

Omthera submits Epanova NDA to FDA for treatment of severe hypertriglyceridemia

A few clinics are focused on helping pregnant women with prescription drug addictions

ERC awards grants to boost research on vaccines

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News